%0 Journal Article %A Edward R. Kastenhuber %A Jared L. Johnson %A Tomer M. Yaron %A Marisa Mercadante %A Lewis C. Cantley %T Evolution of host protease interactions among SARS-CoV-2 variants of concern and related coronaviruses %D 2022 %R 10.1101/2022.06.16.496428 %J bioRxiv %P 2022.06.16.496428 %X Previously, we showed that coagulation factors directly cleave SARS-CoV-2 spike and promote viral entry (Kastenhuber et al., 2022). Here, we show that substitutions in the S1/S2 cleavage site observed in SARS-CoV-2 variants of concern (VOCs) exhibit divergent interactions with host proteases, including factor Xa and furin. Nafamostat remains effective to block coagulation factor-mediated cleavage of variant spike sequences. Furthermore, host protease usage has likely been a selection pressure throughout coronavirus evolution, and we observe convergence of distantly related coronaviruses to attain common host protease interactions, including coagulation factors. Interpretation of genomic surveillance of emerging SARS-CoV-2 variants and future zoonotic spillover is supported by functional characterization of recurrent emerging features.Competing Interest StatementLCC is a founder and member of the SAB of Agios Pharmaceuticals and a founder and former member of the SAB of Ravenna Pharmaceuticals (previously Petra Pharmaceuticals). These companies are developing novel therapies for cancer. LCC holds equity in Agios. LCC laboratory also received some financial support from Ravenna Pharmaceuticals. T.M.Y. is a stockholder and on the board of directors of DESTROKE, Inc., an early-stage start-up developing mobile technology for automated clinical stroke detection. %U https://www.biorxiv.org/content/biorxiv/early/2022/06/16/2022.06.16.496428.full.pdf